Chaired by Dr Anthony Mato
Featuring Dr Deborah Stephens
Featuring Professor Martin Dreyling
Welcome to this expert-led webcast with global experts discussing Bruton's tyrosine kinase (BTK) inhibitors in the treatment of B-cell malignancies.
This program reviews key data presented at the ASH 2021 Annual Meeting, highlighting the advances being made that have the potential to shape future patient care for people with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
This program is designed for, but not limited to, hematologists, oncologists, and other healthcare professionals involved in the management of patients with hematologic malignancies globally.
After participating in the program, learners will be able to:
- Compare the efficacy and safety profiles of approved and emerging BTK inhibitors in the treatment of MCL, CLL and SLL
- Explain how these profiles inform current practice and could shape future patient care
- Incorporate BTK inhibitors in the clinical management of MCL, CLL and SLL
This activity is supported by an educational grant from Lilly.
In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME.